ES2054658T3 - Metodo para la preparacion de una emulsion fisiologicamente aceptable. - Google Patents

Metodo para la preparacion de una emulsion fisiologicamente aceptable.

Info

Publication number
ES2054658T3
ES2054658T3 ES87300454T ES87300454T ES2054658T3 ES 2054658 T3 ES2054658 T3 ES 2054658T3 ES 87300454 T ES87300454 T ES 87300454T ES 87300454 T ES87300454 T ES 87300454T ES 2054658 T3 ES2054658 T3 ES 2054658T3
Authority
ES
Spain
Prior art keywords
preparation
physiologically acceptable
acceptable emulsion
water
highly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87300454T
Other languages
English (en)
Inventor
Leland C Clark Jr
Robert F Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Hemagen PFC LP
Original Assignee
Cincinnati Childrens Hospital Medical Center
Hemagen PFC LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center, Hemagen PFC LP filed Critical Cincinnati Childrens Hospital Medical Center
Application granted granted Critical
Publication of ES2054658T3 publication Critical patent/ES2054658T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EMULSIONES ESTABLES DE COMPUESTOS ORGANICOS ALTAMENTE FLUORADOS PARA UTILIZAR COMO AGENTES DE TRANSPORTE DE OXIGENO, "SANGRES ARTIFICIALES", O SUSTITUTOS DE CELULAS DE SANGRE ROJA, Y COMO AGENTES DE CONTRASTE PARA IMAGEN BIOLOGICA. LAS EMULSIONES COMPRENDEN UN COMPUESTO ALTAMENTE FLUORADO, UN ACEITE QUE NO ES SUSTANCIALMENTE TENSIOACTIVO Y NO SIGNIFICATIVAMENTE SOLUBLE EN AGUA, UN TENSIOACTIVO Y AGUA.
ES87300454T 1986-01-24 1987-01-20 Metodo para la preparacion de una emulsion fisiologicamente aceptable. Expired - Lifetime ES2054658T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82229186A 1986-01-24 1986-01-24
US88371386A 1986-07-09 1986-07-09

Publications (1)

Publication Number Publication Date
ES2054658T3 true ES2054658T3 (es) 1994-08-16

Family

ID=27124629

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87300454T Expired - Lifetime ES2054658T3 (es) 1986-01-24 1987-01-20 Metodo para la preparacion de una emulsion fisiologicamente aceptable.

Country Status (10)

Country Link
EP (1) EP0231091B1 (es)
JP (1) JPH0822815B2 (es)
KR (1) KR870006923A (es)
CN (1) CN87100492A (es)
AU (1) AU598226B2 (es)
CA (1) CA1337969C (es)
DE (1) DE3785054T2 (es)
ES (1) ES2054658T3 (es)
IE (1) IE59175B1 (es)
IL (1) IL81356A (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US5080885A (en) * 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4781676A (en) * 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US4866096A (en) * 1987-03-20 1989-09-12 Air Products And Chemicals, Inc. Stable fluorochemical aqueous emulsions
US4895876A (en) * 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides
US5171755A (en) * 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
WO1991000110A1 (en) * 1989-07-05 1991-01-10 Alliance Pharmaceutical Corp. Fluorocarbon emulsions having saturated phospholipid emulsifiers
GB8919929D0 (en) * 1989-09-04 1989-10-18 Nycomed As Compositions
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5352435A (en) 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
DE4100059C2 (de) * 1991-01-03 1994-08-25 Adatomed Pharma & Med Behandlungsflüssigkeit zum Wiederanlegen (Entfalten) abgelöster Netzhaut an die Aderhaut des Auges
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5146014A (en) * 1991-07-02 1992-09-08 Air Products And Chemicals, Inc. Perfluoroethyldimethyl cyclohexane
FR2679150A1 (fr) * 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
HU218018B (hu) * 1991-09-17 2000-05-28 Sonus Pharmaceuticals Inc. Gázos ultrahang-kontrasztanyag és eljárás ultrahang kontrasztanyaghoz megfelelő gázok kiválasztására
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5295953A (en) * 1992-05-26 1994-03-22 Hemagen/Pfc Method and apparatus for extracorporeal separation of fluorochemicals from whole blood of a patient
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
EP0680341B1 (en) * 1993-01-25 2001-05-09 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
EP1550464A1 (en) 1993-07-30 2005-07-06 IMCOR Pharmaceutical Co. Stabilized microbubble composition for ultrasound
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4405627A1 (de) * 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
US5502094A (en) * 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5658962A (en) 1994-05-20 1997-08-19 Minnesota Mining And Manufacturing Company Omega-hydrofluoroalkyl ethers, precursor carboxylic acids and derivatives thereof, and their preparation and application
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
WO1997025978A1 (en) * 1996-01-15 1997-07-24 BELOYARTSEV, Arkady Felixovich Method of obtaining perfluorocarbon emulsions for medical purposes
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
IL126073A (en) * 1996-03-05 2002-02-10 Acusphere Inc Microencapsulated fluorinated gases for use as imaging agents
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
WO1998010798A1 (en) 1996-09-11 1998-03-19 Imarx Pharmaceutical Corp. Improved methods for diagnostic imaging using a contrast agent and a vasodilator
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US5834519A (en) * 1996-10-11 1998-11-10 Wayne State University Stabilized gas-supersaturated emulsions and suspensions
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2345458A1 (en) 1998-10-12 2000-04-20 Mallinckrodt Inc. Novel ultrasound contrast agents
RU2259819C1 (ru) * 2004-03-01 2005-09-10 Кузнецова Ирина Николаевна Эмульсия перфторорганических соединений медицинского назначения и способ её получения
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
EP3240579B1 (en) 2014-12-31 2022-07-27 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
MX2018013409A (es) 2016-05-04 2019-07-08 Lantheus Medical Imaging Inc Métodos y dispositivos para la preparación de agentes de contraste de ultrasonido.
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
WO2020118307A1 (en) 2018-12-07 2020-06-11 The Regents Of The Univefisity Of California Fluorous metal chelates compositions
WO2022120378A1 (en) 2020-12-04 2022-06-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
KR102342324B1 (ko) * 2020-12-11 2021-12-23 애경케미칼주식회사 불소계 계면활성제 조성물
AU2024339036A1 (en) 2023-09-07 2026-03-12 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5331209B2 (es) * 1973-10-05 1978-09-01
US4252827A (en) * 1979-05-23 1981-02-24 The Green Cross Corporation Oxygen-transferable fluorocarbon emulsion
FR2515198A1 (fr) * 1981-10-22 1983-04-29 Centre Nat Rech Scient Microemulsions aqueuses de fluorocarbures indefiniment stables a une temperature donnee, procede d'obtention et application a titre de transporteurs d'oxygene
JPS5924132B2 (ja) * 1980-12-02 1984-06-07 株式会社 林原生物化学研究所 栄養補給用乳剤の製法
JPS58225013A (ja) * 1982-06-25 1983-12-27 Green Cross Corp:The フルオロカ−ボン乳化製剤
CA1187882A (en) * 1981-11-27 1985-05-28 Kazumasa Yokoyama Perfluoro compound and emulsion thereof
US4490351A (en) * 1982-03-15 1984-12-25 Children's Hospital Medical Center Methods of treating disorders of an eye with liquid perfluorocarbons
JPS5967229A (ja) * 1982-10-08 1984-04-16 Green Cross Corp:The 超音波診断造影剤
WO1984003624A1 (en) * 1983-03-17 1984-09-27 University Patents Inc Method for inhibiting the growth of anaerobes
CA1257828A (en) * 1984-04-16 1989-07-25 William Mccormick Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation
SE8505048L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Nutritionsemulsion med syretransporterande egenskaper

Also Published As

Publication number Publication date
DE3785054D1 (de) 1993-05-06
JPH0822815B2 (ja) 1996-03-06
DE3785054T2 (de) 1993-07-08
IL81356A0 (en) 1987-08-31
EP0231091B1 (en) 1993-03-31
AU6796987A (en) 1987-07-30
IE59175B1 (en) 1994-01-26
CN87100492A (zh) 1987-08-19
EP0231091A1 (en) 1987-08-05
IL81356A (en) 1991-09-16
IE870187L (en) 1987-07-24
CA1337969C (en) 1996-01-23
JPS62228010A (ja) 1987-10-06
KR870006923A (ko) 1987-08-13
AU598226B2 (en) 1990-06-21

Similar Documents

Publication Publication Date Title
ES2054658T3 (es) Metodo para la preparacion de una emulsion fisiologicamente aceptable.
ATE76288T1 (de) Feste pharmaceutische zubereitung mit verlaengerter wirkstofffreigabe und verfahren zur herstellung.
DE3788553D1 (de) Fettsäureester von Polyglycerinpolyglykolethern, ihre Herstellung und ihre Verwendung.
PT73879B (de) 1-carboxyalkanoylindolin-2-carbonsauren verfahren zu ihrer herstellung und pharmazeutische praeparate enthaltend diese verbindungen sowie ihre therapeutische verwendung
SE8304143D0 (sv) Perfluorokemisk emulsion for artificiellt blod
DK166567C (da) Beholder til blod eller blodbestanddele
DE3670577D1 (de) Oel-in-wasser-emulsion.
ATE18355T1 (de) Verwendung von adenosinderivaten zur herstellung eines psychopharmakons.
ES2019590B3 (es) Productos con contenido fosfolipido, fabricacion de los mismos y empleo.
ATE88699T1 (de) Oxidierte diphenylheteroalkane, ihre herstellung und verwendung.
ES2032529T3 (es) Una emulsion de agua y aceite termo-esterilizable.
DE3765985D1 (de) Verwendung von glycofurol zum verfluessigen von arzneimittelzubereitungen fuer das abfuellen in weichgelatinekapseln.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
ATE50407T1 (de) Pyridopyrimidine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
NO891220L (no) Middel som inneholder salicylsyre for behandling av lepidose.
BR8106153A (pt) Processo para a concentracao de uma solucao aquosa viscosa de um polissacarideo solucao aquosa concentrada processo para preparacao de uma solucao de polissacarideos e processo para deslocamento de um fluido atraves de um poco
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
SE8302751D0 (sv) 2(1h)-pyridinon-derivate, ihre herstellung und sie enthaltende pharmazeutische zubereitungen
ES2023396B3 (es) Procedimiento para la elaboracion de nitrilos de acidos grasos y glicerina de glicenido.
SE8404538D0 (sv) Forfaringsteknik med polypropylenglykol for rorelse och blandning av blod med annan vetska i ett kapillerror
ATE37873T1 (de) Verfahren zur herstellung optisch aktiver 1,4dihydropyridine.
ES555162A0 (es) Procedimiento de eliminacion de las aguas de vegetacion en la extraccion de aceite
DE3578577D1 (de) Verfahren zur herstellung von weichgelatinekapseln.
EP0325998A3 (de) 3,3-Dimethyl-hex-5-en-2-onderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE19472T1 (de) Verwendung von 5-phenyl-1,4-benzodoazepinen zur herstellung von analgetisch wirksamen pharmazeutischen zubereitungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 231091

Country of ref document: ES